The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

Aims Acute coronary syndromes (ACSs) are driven by inflammation within coronary plaque. Interleukin-1 (IL-1) has an established role in atherogenesis and the vessel-response to injury. ACS patients have raised serum markers of inflammation. We hypothesized that if IL-1 is a driving influence of inflammation in non-ST elevation ACS (NSTE-ACS), IL-1 inhibition would reduce the inflammatory response at the time of ACS. Methods and results A phase II, double-blinded, randomized, placebo-controlled, study recruited 182 patients with NSTE-ACS, presenting <48 h from onset of chest pain. Treatment was 1:1 allocation to daily, subcutaneous IL-1receptor antagonist (IL-1ra) or placebo for 14 days. Baseline characteristics were well matched. Treatment compliance was 85% at 7 days. The primary endpoint (area-under-the-curve for C-reactive protein over the first 7 days) was: IL-1ra group, 21.98 mg day/L (95%CI 16.31–29.64); placebo group, 43.5 mg day/L (31.15–60.75) (geometric mean ratio = 0.51 mg/L; 95%CI 0.32–0.79; P = 0.0028). In the IL-1ra group, 14-day achieved high-sensitive C-reactive protein (P < 0.0001) and IL-6 levels (P = 0.02) were lower than Day 1. Sixteen days after discontinuation of treatment (Day 30) high-sensitive C-reactive protein levels had risen again in the IL-1ra group [IL-1ra; 3.50 mg/L (2.65–4.62): placebo; 2.21 mg/L (1.67–2.92), P = 0.022]. MACE at Day 30 and 3 months was similar but at 1 year there was a significant excess of events in the IL-1ra group. Conclusion IL-1 drives C-reactive protein elevation at the time of NSTE-ACS. Following 14 days IL-1ra treatment inflammatory markers were reduced. These results show the importance of IL-1 as a target in ACS, but also indicate the need for additional studies with anti-IL-1 therapy in ACS to assess duration and safety. Clinical Trial Registration EUCTR: 2006-001767-31-GB: www.clinicaltrialsregister.eu/ctr-search/trial/2006-001767-31/GB.

[1]  P. Libby.  Mechanisms of acute coronary syndromes and their implications for therapy. , 2013, The New England journal of medicine.

[2]  G. Biondi-Zoccai,et al.  Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. , 2013, The American journal of cardiology.

[3]  J. Gallacher,et al.  C-reactive protein, fibrinogen, and cardiovascular disease prediction. , 2012, The New England journal of medicine.

[4]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[5]  A. Hingorani,et al.  Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial , 2011, European heart journal.

[6]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[7]  J. Kaski,et al.  A comparative study of biomarkers for risk prediction in acute coronary syndrome-Results of the SIESTA (Systemic Inflammation Evaluation in non-ST-elevation Acute coronary syndrome) study. , 2010, Atherosclerosis.

[8]  Gary Shaw,et al.  Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding , 2009, PloS one.

[9]  A. Hall,et al.  Investigation of the effect of Interleukin-1 receptor antagonist (IL-1ra) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study) , 2008, Trials.

[10]  David Evans,et al.  Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. , 2006, The American journal of pathology.

[11]  M. Braddock,et al.  Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis. , 2005, American heart journal.

[12]  L. Jonasson,et al.  Circulating levels of proinflammatory cytokines and neutrophil-platelet aggregates in patients with coronary artery disease. , 2005, The American journal of cardiology.

[13]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[14]  F. Crea,et al.  Widespread coronary inflammation in unstable angina. , 2003, The New England journal of medicine.

[15]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[16]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[17]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[18]  C. Glass,et al.  Atherosclerosis: The Road Ahead Review , 2001 .

[19]  E. Vicaut,et al.  Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. , 2000, Journal of the American College of Cardiology.

[20]  J. Gunn,et al.  Temporal and spatial distribution of interleukin-1β in balloon injured porcine coronary arteries , 1999 .

[21]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[22]  A. Rebuzzi,et al.  Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. , 1999, Circulation.

[23]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[24]  J. Gunn,et al.  Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries. , 1999, Cardiovascular research.

[25]  R J Glynn,et al.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.

[26]  J. Arnal,et al.  Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. , 1998, Circulation.

[27]  Joseph L Schafer,et al.  Analysis of Incomplete Multivariate Data , 1997 .

[28]  C. Holt,et al.  Interleukin-1β in Coronary Arteries of Patients With Ischemic Heart Disease , 1996 .

[29]  C. Holt,et al.  Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[30]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[31]  A. Mantovani,et al.  Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. , 1993, Science.

[32]  C. Dinarello,et al.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. , 1990, Blood.

[33]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.